Evidence map›Paper›PMID 40684829›Full record

SynthesisContraception2025

Contraceptive use among women with inflammatory bowel disease: An updated systematic review.

Lauren B Zapata, Emily M Snyder, Naomi K Tepper, Kathryn M Curtis

Abstract readSystematic Review
In one paragraph

Synthesis in Contraception, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lauren B ZapataDivision of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service Commissioned Corps, Atlanta, GA, United States. Electronic address: lzapata@cdc.gov.
Emily M SnyderDivision of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States; Oak Ridge Institute for Science and Education, Oak Ridge, TN, United States.
Naomi K TepperDivision of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service Commissioned Corps, Atlanta, GA, United States.
Kathryn M CurtisDivision of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectivesHormonal contraceptive use by women with inflammatory bowel disease (IBD) might affect risk of adverse outcomes or contraceptive effectiveness. Our objective was to update a previous systematic review on the safety and effectiveness of contraceptive use among women with IBD. STUDY

designWe searched multiple databases from inception through July 15, 2024 for articles on contraception and IBD. Outcomes were IBD disease activity or relapse, other adverse health outcomes, and oral contraceptive (OC) effectiveness. We assessed risk of bias for each study and certainty of evidence for most outcomes.

resultsFifteen articles met our inclusion criteria; eight were new. Twelve had high risk of bias and three moderate risk. One cohort study found lower odds of IBD symptoms among hormonal contraceptive users compared with non-hormonal users, but higher odds of intestinal inflammation over 1 year. Nine cohort studies found inconsistent results regarding OC use and disease activity or relapse, with increased and decreased associations; most were not statistically significant. Two cohort studies found no statistically significant associations between OC use and venous thromboembolism (VTE) among IBD patients. One study found no statistically significant association between OC use and abnormal cervical smears. Two pharmacokinetic studies suggested no differences in plasma concentrations of steroid hormones after oral ingestion among participants with and without IBD. We found no evidence examining risk of osteoporosis or osteopenia among women with IBD using contraception.

conclusionsLimited evidence suggested inconsistent findings for increased risk of disease activity or relapse among women with IBD using hormonal contraception (very low certainty of evidence), no differences in other adverse events (very low certainty of evidence), and no differences in contraceptive hormone concentrations. IMPLICATIONS: This updated review expands upon the previous review with eight newly identified studies. However, evidence is still limited in quantity and quality, with inconsistent findings on risk of disease activity or relapse and lack of high-quality evidence on risk of VTE and contraceptive effectiveness. Information in this review may be used by guideline development groups that publish evidence-based contraception guidance for clinicians and patients. Further research can focus on these gaps to provide information needed by women with IBD as they make contraceptive choices.

Indexed as

ContraceptionContraceptives, Oral, HormonalInflammatory Bowel DiseasesContraceptive EffectivenessContraceptives, OralFemaleHumansContraceptives, OralContraceptives, Oral, HormonalContraceptionContraceptive effectivenessInflammatory bowel diseaseRelapseSystematic reviewVenous thromboembolism

Identifiers

PMID40684829
PMCPMC12404129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.